RAPT Therapeutics RAPT 深 沪
交易中 09-05 11:27:52 美东时间
13.31
+0.580
+4.56%
华盛通- 最 高13.37
- 今 开12.68
- 成交量 2.46万股
- 最 低 12.5529
- 昨 收 12.73
- 总市值 2.20亿
- 52周最高 26.56
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.6656
- 委 比 -72.50%
- 总股本 1653.61万
- 历史最高 409.68
- 量 比 1.90
- 振 幅 6.42%
- 历史最低 5.6656
- 每 手 1
- 风险率 3.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Wells Fargo Maintains Overweight on RAPT Therapeutics, Lowers Price Target to $38
Wells Fargo analyst Yanan Zhu maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and lowers the price target from $51 to $38.
08-08 23:32
RAPT Therapeutics GAAP EPS of -$0.65
RAPT Therapeutics press release (NASDAQ:RAPT): Q2 GAAP EPS of -$0.65. As of June 30, 2025, the Company had cash and cash equivalents and marketable securities of $168.9 million. More on RAPT Therape...
08-07 21:20
RAPT Therapeutics Q2 EPS $(0.65) Misses $(0.63) Estimate
RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.63) by 2.69 percent. This is a 88.58 percent increase over losses of $(5.69) per share
08-07 20:06
RAPT Therapeutics Reports Second Quarter 2025 Financial Results
RAPT Therapeutics reported Q2 and H1 2025 financial results, highlighting a net loss of $17.6 million for Q2 and $34.8 million for H1, compared to $27.7 million and $58.2 million in 2024. R&D expenses decreased by $10.3 million and $23.0 million, while G&A expenses increased slightly. The company strengthened its team and pipeline, with plans to initiate a Phase 2b trial for RPT904 in food allergy later this year and report topline results from J...
08-07 12:00
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
Rapport Therapeutics reported that the Phase 2a trial of RAP-219 for drug-resistant focal onset seizures is fully enrolled and expects topline results in September 2025. Additionally, the Phase 2 trial for bipolar mania is ongoing with results anticipated in the first half of 2027. The company ended Q2 2025 with $260.4 million in cash, supporting operations through 2026. Second-quarter net loss was $26.7 million, with R&D and G&A expenses increas...
08-07 11:00
美股大行评级 | 丰业银行上调Meta目标价从525美元升至675美元；恩智浦获"超配"评级，目标价从190美元升至220美元
今日重点评级关注：瑞杰金融：维持Antero Resources Corp."强烈买入"评级，目标价从57美元升至58美元；美银证券：维持和黄医药"买入"评级，目标价从27美元升至28美元
07-23 09:42
LifeSci Capital Initiates Coverage On RAPT Therapeutics with Outperform Rating, Announces Price Target of $31
LifeSci Capital initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Outperform rating and announces Price Target of $31.
07-23 05:08
HC Wainwright & Co. Maintains Buy on RAPT Therapeutics, Raises Price Target to $27
HC Wainwright & Co. analyst Emily Bodnar maintains RAPT Therapeutics (NASDAQ:RAPT) with a Buy and raises the price target from $6 to $27.
07-10 18:25
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
RAPT Therapeutics announced the addition of Scott Braunstein, M.D., to its Audit Committee and Ashley Dombkowski, Ph.D., to its Nominating and Corporate Governance Committee. Both bring extensive industry experience. RAPT’s lead product, RPT904, a novel monoclonal antibody targeting free IgE, is completing Phase 2 trials in chronic spontaneous urticaria and asthma, with plans for a Phase 2 study in food allergy later this year. The company aims t...
06-23 12:00
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
RAPT Therapeutics, Inc. announced a 1-for-8 reverse stock split effective June 16, 2025. The company's common stock will continue trading on the Nasdaq Global Market under the same symbol "RAPT" with a new CUSIP number. The reverse split will reduce outstanding shares from approximately 132.3 million to 16.5 million, while increasing the number of authorized shares available for future issuance. Adjustments will also be made to pre-funded warrant...
06-13 13:00
